Daily Trades
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
Shares jumped 45% yesterday when Bloomberg News broke the story that "Sanofi is exploring acquisition of cancer drug maker Mirati."
- Dylan Jovine
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
deal of the month
Categories
Israel vs. Iran: The Mistake That Could Drag the U.S. into War
The Looming Threat to Nvidia and AI
The Empire Strikes Back: DOJ's Latest Move Against Apple
Recent posts
Tags
Connect with Us
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
Shares jumped 45% yesterday when Bloomberg News broke the story that "Sanofi is exploring acquisition of cancer drug maker Mirati."
- Dylan Jovine
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
Today I want to talk to you about KRAS mutations in cancer treatment. But first, we have three stocks to sell today. We’ll be taking profits on two and a loss on one.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.